George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIlika Plc Regulatory News (IKA)

Share Price Information for Ilika Plc (IKA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 27.90
Bid: 27.00
Ask: 28.00
Change: 0.00 (0.00%)
Spread: 1.00 (3.704%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 27.90
IKA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Final Results

11 Jul 2017 07:00

RNS Number : 6540K
Ilika plc
11 July 2017
 

ILIKA plc

(The "Company" or the "Group")

 

Final Results

 

Financial Statements for year ended 30 April 2017

 

Ilika (AIM: IKA), the accelerated materials innovation company, announces its audited full-year results for the year ended 30 April 2017.

Operational highlights:

· Launch of StereaxTM P180, the extended temperature range solid-state battery

· Collaboration with a bioelectronics company to develop Stereax for miniature medical implants

· Collaboration with Sharp to integrate Stereax solid-state batteries with Sharp's photovoltaic technology

· Grant of patents protecting Stereax technology

· Award of grant to develop protected anodes for lithium sulphur batteries with Johnson Matthey

· Award of grant to develop photonic materials for Hard Disk Drives with Seagate

· Collaboration with Toyota Research Institute to identify new advanced battery materials and fuel cell catalysts that can power future zero-emissions and carbon-neutral vehicles

· Grant of patents protecting unique High-Throughput Vapour Deposition method

 

Financial highlights:

· Revenues of £1.1m (2016: £0.6m)

· Net Loss for the year of £3.5m (2016: £3.5m)

· Loss per share of 4.8p (2016: 5.2p)

· Cash, cash equivalents and bank deposits of £5.4m (2016: £3.0m) post fundraising of £5.8m (net) in the year

Commenting on the results Ilika's Chairman, Mike Inglis, said: "I have been very encouraged by the operational and commercial progress made at Ilika this year. We followed up the launch of our first Stereax product, the M250, with the launch of a high temperature battery, the P180, for industrial IoT applications. Using our Stereax pilot line we have been able to supply samples of our batteries to potential customers and support the discussions being led by our commercial team around the globe. The first commercial engagements for Stereax have been secured and I anticipate these, and other interactions, to lead to closer engagements going forward. I am also pleased to see revenues tick up this year, which based on our strong current order book, is a trend I expect to see continuing in 2017/18."

 

 

 

STRATEGIC REPORT

 

The Directors present their Strategic Report for the year ended 30th April 2017.

 

Principal activities

 

Ilika plc is the holding company for Ilika Technologies Limited, a pioneer in solid-state battery technology and materials innovation. Ilika has developed ground-breaking solid-state battery technology to meet the demands of the Internet of Things (IoT). Ilika has a unique, patent protected high throughput technology platform which accelerates the discovery of new and patentable materials for identified end uses in the automotive, aeronautical and electronics sectors.

 

Business Strategy

 

The Company's strategy is to commercialise the intellectual property (IP) that it has created and continues to create, in its Stereax solid-state battery programme. The Company has developed miniature batteries as an enabler for wireless sensors used in industrial and medical applications.

 

The Company's objective is to have its batteries integrated into market-leading products sold by leading commercialisation partners around the world. The Company generally expects these end-products to fit into or create end-markets worth in excess of $1 billion per year, in which the Directors believe a number of the Company's commercialisation partners are positioned to have a leading share.

 

The Company uses its processes to discover and commercialise novel materials for integration into products with high value end-markets. In order to ensure a high probability of commercial success, the Company prefers to develop these materials in collaboration with large multinational companies, which have the expertise to bring new products to market to address unmet needs in their sectors. The Company aims to create IP such that it will benefit from commercialisation rewards associated with the ultimate generally adopted technology.

 

The Company is pursuing its objectives through the following strategies:

· Developing leading-edge high throughput development processes;

· Partnering with companies committed to developing and globally commercialising jointly developed products;

· Using high throughput processes to invent patentable functional materials across addressable markets in the automotive, aeronautical and electronic components sectors; and

· Development of valuable products through the application of functional materials.

 

The Company's revenue model involves three phases of activity: a) commercially-funded and grant-funded development projects; b) IP licensing; c) receipt of royalties when products incorporating Company IP reach market. The Company is currently in the first phase of activity, with its revenue being generated from development fees. The Company has built a pipeline of licensing opportunities to support the start of its second phase of revenue generation.

 

 

 

Operating Review

 

Solid-State Batteries

Ilika has been working with solid-state battery technology since 2008 and has developed a type of lithium-ion battery, which, instead of using liquid or polymer electrolyte, uses a ceramic ion conductor, making it particularly suitable for micro-battery applications. Battery technology is a key challenge in the electronics sector, with IoT being a key driver of growth and battery technology development.

 

IoT devices offer a different set of battery challenges compared to other electronic devices. They have similar pressures, such as cost and availability, but they also have some specific requirements:

 

o Small size in both footprint and thickness

o Ability to be trickle charged

o Charged only when an energy harvester can get energy

o Longer life span to match those of sensors and MCUs

o Support wider temperature ranges

 

Ilika's solid-state batteries have several benefits over currently available lithium-ion batteries:

 

o 6x faster to charge

o Energy dense in a small footprint

o 10x lower leakage currents

o Non-flammable

o Can be integrated into IC components to reduce end device size

 

Battery Product Launch

In April 2016, Ilika launched its Stereax™ M250 solid-state battery IP. This is a miniaturised solid-state battery for IoT devices and is designed to address the key challenge of always-on, self-charging and efficient energy. Ilika Stereax™ batteries use patented materials and processes enabling superior energy density per battery footprint, up to 40% improvement on current solid-state solutions. Ilika's batteries do not contain any free lithium which makes them more moisture resistant. The Stereax™ M250 operates in a temperature range to over 100°C, 30°C higher than existing solid-state products. 

 

In April 2017, Ilika launched the Stereax™ P180 with the additional benefits of support for extended temperature ranges from -40°C up to +150°C. This range is required for many Industrial IoT and Automotive end applications enabling always on, self-charging energy efficient IoT solutions for more demanding environments. As the trend towards digitising industrial processes gathers momentum there is a growing requirement for components with enhanced tolerance to temperature, moisture and vibration.

 

Battery Roadmap

The Ilika Stereax™ roadmap focuses on three main areas:

 

· Performance. The hostile environment of many industrial applications requires tolerance to extended temperature ranges and vibration. The Stereax™ P180 is the first solid-state battery to address these needs and its launch will be supported by further development in this area.

 

· Capacity. For the launch of both the M250 and the P180, Ilika designed and made some wireless sensor nodes measuring temperature, humidity and light intensity. The power requirements of sensors does vary, depending on the nature of the sensor. For example, a motion detector has a higher power requirement than a temperature sensor. In order to be able to power a wider range of devices, Ilika is increasing the energy footprint of its batteries. Increasing the amount of energy for a given active footprint can be achieved by utilising Ilika's patented stacking feature, which allows multiple cells to be stacked on top of one another.

 

· Miniaturisation. This looks at progressively smaller footprints at smaller currents (µAh), making them ideal for small sensor driven devices.

 

Medical

During the year, the company announced a two-year collaborative project with a well-financed bioelectronics company to develop a battery for miniature medical implants to provide treatments for serious health conditions, through the body's own nervous system. The programme is supported by Innovate UK and the Medical Research Council.

 

Integrated energy harvester and battery

During the year the company announced a two-year collaborative project with Sharp Laboratories of Europe (now known as Lightricity) to create an autonomous energy harvesting power source which will involve the integration of Ilika's solid-state battery with Lightricity's photovoltaic (PV) technology creating the world's first fully integrated thin-film power source. This integration project is aligned with the development track for increasing the capacity of Stereax batteries.

 

Patent Position

In March 2017, Ilika announced it had received a granted Patent in the USA for its patent application supporting solid-state batteries jointly filed with Toyota Motor Company in July 2011. This Notice in USA followed the successful British grant in April 2014, the Notice of Grant in Europe in July 2015 and in China in September 2015. This patent family is one of the two earliest filings of a growing portfolio of IP exemplifying Ilika's unique approach to solid-state battery production using evaporation sources. The more recent applications in the portfolio contain both jointly-owned and solely owned IP.

 

Materials Portfolio Activities

Solid-state battery development accounted for about 60% of activity in the year, the Company was also active in the development of aerospace alloys and materials for electronics applications.

 

Energy Materials

In August 2016, Ilika announced that it is taking part in a three-year project to develop protected anodes for lithium sulphur batteries, led by Johnson Matthey Plc. This project is developing an innovative protected lithium anode approach to discover new electrolyte composition options and fabricate a free-standing, lithium-containing protected anode/separator for integration into pouch cells. The novel protected anode is intended to mitigate a commonly experienced problem in lithium-sulphur cells, the so-called polysulphide shuttle effect, leading to enhanced performance cells that can be made with existing cell fabrication methods. The pouch cells being developed in this project are high capacity, low cost batteries for large scale renewable energy storage and therefore address a distinct market segment to the Internet of Things (IoT) applications for which Ilika's Stereax™ batteries are designed

 

In March 2017, Ilika announced a $1m commercially funded program with the Toyota Research Institute ('TRI') to develop game changing energy materials. The program is part of a $35 million investment by TRI over the next four years in research that uses artificial intelligence to accelerate the design and discovery of advanced materials. In this initial one year collaboration with the Company, Ilika's unique high throughput platform is being used to make and test candidate materials, which have been identified using simulation, machine learning and artificial intelligence strategies. Promising materials will be further scaled-up by Toyota and its suppliers for deployment in its future low-emission vehicles.

 

Aerospace Alloys

Ilika has continued in its lead role in a £2.15m, three year Innovate UK grant funded project with BAE Systems, GKN, Reliance Precision Engineering and the University of Sheffield. The project started in September 2015 to develop a new generation of self-healing alloys suitable for additive manufacturing (AM) processes and to develop a metallic manufacturing process that takes advantage of the flexibility of AM and the precision of subtractive manufacturing. This will enable the manufacture of novel components with critical feature tolerances, meeting the challenges faced in the design of mechanisms for the aerospace industry with lower weight, structural integrity and functional performance.

 

Additionally, Ilika has continued in its role leading a £1.33 million three year Innovate UK funded project with Rolls Royce, Diamond Light Source and the University of Cambridge to develop new superalloy compositions for gas turbine engines with better thermo efficiency than current alloys. The alloys are designed to increase gas turbine performance, reducing CO2 emissions and noise levels at take-off. This program is due to continue until September 2017.

 

Electronic Materials

The two-year project with Seagate and the University of Southampton ("UoS"), announced in February 2016, is providing a demonstration of "2D materials" for Hard Disk Drive ('HDD') applications. 2D materials are crystalline materials consisting of a single layer of atoms. Materials with superior nanophotonic properties are being developed to achieve improved hard drive performance and reliability. These materials must operate at temperatures of up to 300⁰C for thousands of hours, requiring extremely robust nanomaterials that have specific photonic properties allowing light energy to be conducted

 

In February 2017, the Company announced a further 18 month project with Seagate to develop photonic materials and processes for HDD technology. This project will deliver a process for photonic material development with improved data capacity using engineered materials to enable Heat Assisted Magnetic Recording ("HAMR"). Photonic materials, engineered with new process methods, will boost performance and reliability for HAMR hard drives, decreasing time to market.

 

Key performance indicators ('KPIs')

 

The board considers that the most important KPIs are technical and operational and relate to the sales pipeline and engagement of commercialisation partners resulting from the progress of the technical development programmes outlined above.

 

The most important financial KPIs are the cash position and the operating loss of the Group, which remain under constant focus and which are considered in the financial review.

 

 

 

FINANCIAL REVIEW

The Financial Review should be read in conjunction with the consolidated financial statements of the Company and Ilika Technologies Limited (together the 'Group') and the notes thereto. The consolidated financial statements are presented under International Financial Reporting Standards as adopted by the European Union. The financial statements of the Company continue to be prepared in accordance with International Financial Reporting Standards as adopted by the EU.

 

Statement of Comprehensive Income

 

Revenues

Revenue, all from continuing activities, for the year ended 30th April 2017 was £1.1m (2016: £0.6m). This includes £739k of grant income recognised from six projects that the company has in progress with Innovate UK (2016: £455k from three programs). Details of the various programmes are provided in the Materials Portfolio activities.

 

More of the Company's activities are supported by grant or commercial funding than was the case in the prior year, where operational resources were more heavily devoted to the internally funded battery development programme. 

 

Administrative expenses and losses for the period

Total administrative costs for the year were slightly increased at £3.9m in 2017 relative to £3.8m in 2016. This increase is attributable to the increased spend on research and development in the year, particularly associated with the solid-state battery development program.

Combined cost of sales and administrative expenses were £4.3m in the year which is up from the £4.1m for 2016 and is associated with the increased level of commercial and grant supported programs.

 

Options were granted in the year and, taken together with a full year's charge for options that were granted last year, gave rise to a share based payment charge than increased by around £0.2m to £0.5m.

This increased accounting adjustment meant that loss on continuing activities before tax remained at £3.9m.

 

Statement of financial position and cash flows

At 30th April 2017, net assets amounted to £6.2m (2016: £3.4m), including net funds of £5.4m (2016: £3.0m).

 

The principal elements of the £2.4m increase over the year ended 30 April 2017 in net funds were:

· Funds raised in the year £5.8m (2016 £0.0m)

· Cash used in operations of £3.6m (2016: £3.3m);

· Purchase of plant, property and equipment of £0.2m (2016: £0.1m)

· Research and development tax credits received of £0.4m (2016: £0.3m);

 

On 18th October 2016, gross funds of £6.3m was raised from new and existing institutional shareholders to strengthen the Group's balance sheet and provide additional working capital during the solid-state battery commercialisation process. Expenses of £465k were incurred in the placing.

 

Trade receivables at the year-end increased from £28k to £133k, due to the start of the program with TRI. This balance was within payment terms and has been received post year end.

 

Accrued income at the year-end increased from £117k to £371k. This is revenue recognised from the six grant funded programs with Innovate UK relative to the three programs last year.

 

£75k of the increase in other receivables in the year is the funds placed in a bond account, taking it to £150k to cover the dilapidations provision shown in note 12.

 

Treasury policy and financial risk management

Details of the risks associated with financial instruments are shown in note 13.

 

 

PRINCIPAL RISKS AND UNCERTAINTIES

 

Commercial risk

The Group is subject to competition from competitors who may develop more advanced and less expensive alternative technology platforms, both for existing materials and for those materials currently under development. The Group is largely dependent on its partners to commercialise the end-products containing the Group's materials.

 

The Group seeks to reduce this risk by continually assessing competitive technologies and competitors. The Group seeks to commercialise materials through multiple channels to reduce overreliance on individual partners and, in agreements with partners, it ensures that there are commercialisation milestones which must be met for the partner to retain the rights to commercialise the materials.

 

Financial risk

The Group is reliant on a small number of significant customers and partners. Termination of these agreements could have a material adverse effect on the Group's results or operations or financial condition. The Group expects to incur further operating losses as progress on development programmes continue. There can be no assurance that the Group will ever achieve significant revenues or profitability.

 

The Group seeks to reduce this risk by broadening the number of customers and partners and thereby reduce reliance on individual significant companies. The Group applies for Research and Development tax credits to help mitigate its investment in these activities.

 

Intellectual property risk

The Group faces the risk that intellectual property rights necessary to exploit research and development efforts may not be adequately secured or defended. The Group's intellectual property may also become obsolete before the products and services can be fully commercialised.

 

The Group seeks to reduce this risk by employing in-house staff with extensive global experience of patenting and licensing using commercially available patent searching and landscaping software. External patent agents and attorneys are used to advise on the drafting and filing of patent applications.

 

Dependence on senior management and key staff

Certain members of staff are considered vital to the successful development of the business. Failure to continue to attract and retain such highly skilled individuals could adversely affect operational results.

 

The Group seeks to reduce this risk by offering appropriate incentives to staff through competitive salary packages and participation in long-term share option schemes.

 

Brexit risk

The Group has reviewed the potential impact of Brexit on the risks identified above and believes that whilst intellectual property risk will remain largely unaffected, there may be an impact in the future regarding the Group's ability to attract and retain highly skilled individuals.

 

The Group is alert to and continuously reviewing this potential risk and formulating its response at the appropriate time.

 

 

 

 

 

By order of the Board

 

 

 

 

 

 

Mike Inglis Graeme Purdy

Chairman CEO

 

11th July 2017 

DIRECTORS' REPORT

 

Directors

The Directors who served on the board of Ilika during the year and to the date of this report were as follows:

 

Executive

Mr S Boydell (FD and Company Secretary)

Prof. B. E. Hayden (CSO)

Mr G. Purdy (CEO)

 

Non-Executive

Mr M. Inglis (Chairman)

Ms. C Spottiswoode CBE

Prof. Sir W Wakeham (Senior Independent Director)

Prof. K Jackson

 

Research and development costs

In accordance with the policy outlined in note 1, the Group incurred research and development expenditure of £2,110,843 in the year (2016: £2,057,966). Commentary on the major activities is given in the Strategic Report.

 

Financial instruments

The use of financial instruments and financial risk management policies is covered in the Strategic Report and also in note 13 of the financial statements.

 

Future developments

Information on the future developments of the business are included in the Strategic Report.

 

Dividends

The Directors do not recommend the payment of a dividend.

 

 

 

Directors' interests in ordinary shares

The directors, who held office at 30th April 2017, had the following interests in the ordinary shares of the Company:

 

Number of shares

 

1st May 2016

30th April 2017

 

 

 

G Purdy

589,427

609,427

C Spottiswoode

45,454

45,454

S Boydell

9,090

9,090

M Inglis

65,000

115,000

W Wakeham

-

20,000

K Jackson

-

20,000

B Hayden*

-

-

 

* B Hayden had an interest in preference shares of the Company amounting to 426,300 at 1st May 2016 and at 30th April 2017.

 

Between 30th April 2017 and the date of this report, there has been no change in the interests of directors in shares as disclosed in this report.

 

Substantial shareholdings

On 28th June 2017 the Company had been notified of the following holdings of more than 3% or more of the issued share capital of the Company.

 

Shareholder

No. of ordinary shares

% shareholding

Charles Stanley Group plc

9,863,826

15.0

Henderson Global

11,300,000

14.4

Ruffer LLP

6,715,999

8.6

IP Group plc

6,358,779

8.1

Baillie Gifford & Co.

5,905,706

7.5

Parkwalk Advisors

5,300,000

6.8

Richard Griffiths

2,574,836

3.3

Southampton Asset Management

2,349,900

3.0

 

Post balance sheet events

There are no significant post balance sheet events from the 30th April 2017 to the signing of this report.

Auditors

All the current directors have taken all the steps that they ought to have taken to make themselves aware of any information needed by the Company's Auditors for the purposes of their audit and to establish that the Auditors are aware of that information. The Directors are not aware of any relevant audit information of which the Auditors are unaware.

 

A resolution to re-appoint BDO LLP will be proposed at the next Annual General Meeting.

By order of the board

 

Steve Boydell

Company Secretary

DIRECTORS' REMUNERATION REPORT

Remuneration Committee

The Group's remuneration policy is the responsibility of the Remuneration Committee (the 'Committee'). The terms of reference of the Committee are outlined in the Corporate Governance Statement. The Committee members are Mike Inglis (Chairman), Clare Spottiswoode, Prof Keith Jackson and Prof Sir William Wakeham, all of whom are independent non-executive directors.

 

The Chief Executive Officer and certain executives may be invited to attend Committee meetings to assist with its deliberations, but no executive is present when their own remuneration is being discussed.

 

Remuneration policy

(i) Executive remuneration

The Committee has a duty to establish a remuneration policy which will enable it to attract and retain individuals of the highest calibre to run the Group. Its policy is to ensure that the executive remuneration packages of executive directors and the fee of the Chairman are appropriate given performance, scale of responsibility, experience, and consideration of the remuneration packages for similar executive positions in companies it considers to be comparable. Packages are structured to motivate executives to achieve the highest level of performance in line with the best interests of shareholders. A significant proportion of the total remuneration package, in the form of bonus and share options, is performance driven and has been constructed following consultation with major shareholders.

 

Components of remuneration

Component

Purpose and link to strategy

Operation

Performance metrics

Base salary

To attract and retain talent.

 

 

 

 

Reflecting individual's role, experience and performance. Base salaries are reviewed annually in January.

Take into account Group and individual performance, external benchmark information and internal relativities

Benefits and Pension

To offer market competitive package

Contribution to the executive director's individual money purchase scheme (at between 8% and 10% of base salary) and critical illness cover

n/a

Short‑Term Incentive Plan - annual

performance related bonus

Rewards the achievement of short‑term financial and strategic project milestones

Maximum bonus of base salary: 100% CEO, 60% CSO and 40% CFO. 50% of the bonus is payable in cash and 50% is deferred into shares (using nominal cost options) for one year, subject to continued employment

Delivery of exceptional performance against a series of financial, commercial and technology objectives.

Long‑Term Incentive Plan - restricted share unit awards

Incentivise, retain and reward the executive directors for successfully taking the Company through the next stage of its growth.

Ilika plc Long Term Incentive Plan 2015 (the "LTIP"), was adopted by shareholders at the 2015 AGM

Single awards of share options with an exercise price of the nominal value of the shares were made which will vest after three years

Awards vest to the extent that challenging share price targets have been met.

 

Shareholding guidelines

To increase shareholder alignment

100% of the net of tax share awards which vest must be retained until the following guidelines are met:

CEO 300% of salary

CSO 250% of salary

CFO 150% of salary

n/a

 

 

 

(ii) Chairman and non-executive Director remuneration

The Chairman, Mr Inglis receives a fixed fee of £65,975 per annum. Clare Spottiswoode, Prof Sir William Wakeham and Prof Keith Jackson received a fixed fee of £32,988 per annum. The fixed fee covers preparation for and attendance at meetings of the full Board and committees thereof. The Chairman and the executive directors are responsible for setting the level of non-executive remuneration. The non-executive directors are also reimbursed for all reasonable expenses incurred in attending meetings.

 

All remuneration policies will be reviewed regularly to maintain adherence with best market practice as appropriate.

 

Directors' remuneration

The aggregate remuneration received by directors who served during the year ended 30th April 2017 and 30th April 2016 was as follows:

 

 

 

Basic

salary

Benefits in kind

 

 

Bonus

Total

Short term benefits

Pension

Total

 

£

£

£

£

£

£

Year to 30th April 2017

 

 

 

 

 

 

G Purdy

191,000

615

50,250

241,865

30,100

271,965

S Boydell

123,429

399

13,043

136,871

17,434

154,305

B Hayden*

64,320

 

19,372

83,692

-

83,692

M Inglis

65,325

-

-

65,325

-

65,325

K Jackson

32,662

-

-

32,662

-

32,662

W Wakeham

32,662

-

-

32,662

-

32,662

C Spottiswoode

32,662

-

-

32,662

-

32,662

 

------

------

------

------

------

------

 

542,060

1,014

82,665

625,739

47,534

673,273

 

------

------

------

------

------

------

Year to 30th April 2016

 

 

 

 

 

 

G Purdy

190,000

671

30,000

220,671

30,000

250,671

S Boydell

120,260

423

10,181

130,864

17,181

148,045

B Hayden*

64,000

-

16,095

80,095

-

80,095

M Inglis

54,167

-

-

54,167

-

54,167

J Boyer

25,500

-

-

25,500

-

25,500

K Jackson

32,500

-

-

32,500

-

32,500

W Wakeham

32,500

-

-

32,500

-

32,500

C Spottiswoode

32,500

-

-

32,500

-

32,500

 

------

------

------

------

------

------

 

551,427

1,094

56,276

608,797

47,181

655,978

 

------

------

------

------

------

------

*B Hayden is employed by the University of Southampton. The amounts disclosed in the table above relate to payments made directly to B Hayden. The University of Southampton recharged employment costs of £72,859 to the company in the year in respect of B Hayden. (2016: £63,171).

 

Benefits in kind include critical illness cover.

 

Share options

 

The share options of the directors are set out below:

 

 

Unapproved

2016

Number

2017

Number 1

Exercise Price

 

Expiry date

Performance Conditions

G Purdy

136,200

136,200

80p

 July 2017

n/a

G Purdy

1,050,000

1,050,000

51p

May 2020

n/a

G Purdy2

872,727

872,727

1p

September 2025

See note 4

B Hayden

59,300

59,300

80p

 July 2017

n/a

B Hayden

525,000

525,000

51p

May 2020

n/a

B Hayden

177,900

177,900

81.5p

February 2025

See note 4

B Hayden2

527,272

527,272

1p

September 2025

See note 4

S Boydell

117,600

117,600

51p

May 2020

n/a

S Boydell2

274,909

274,909

1p

September 2025

See note 4

W Wakeham

65,100

65,100

51p

May 2020

n/a

C Spottiswoode

50,100

50,100

51p

May 2020

n/a

M Inglis3

120,000

120,000

68.75p

September 2025

See note 4

K Jackson3

40,000

40,000

68.75p

September 2025

See note 4

 

 

 

 

 

 

Approved

 

 

 

 

 

G Purdy

26,500

26,500

80p

May 2017

n/a

G Purdy

245,300

245,300

81.5p

February 2025

See note 4

S Boydell

90,000

90,000

80p

December 2019

n/a

S Boydell

154,600

154,600

81.5p

February 2025

See note 4

 

1) There was no movement in the share options of the directors in the year.

2) Shareholders' approval to adopt and establish the Ilika plc Long Term Incentive Plan 2015 (the "LTIP") was received at the AGM in September 2015.

3) Shareholders' approval to grant unapproved share options to the non-executive directors Mike Inglis and Professor Keith Jackson was received at the AGM in September 2015.

4) These awards will vest on the achievement of the following share price targets, assessed over a three year performance period:

(a) Less than 50% growth in share price - no vesting

(b) 50% growth in share price - 25% of the shares subject to award will vest

(c) 100% growth in share price - 75% of the shares subject to award will vest

(d) 200% growth in share price - 100% of the shares subject to award will vest

Awards will vest between points (b) and (c) and between (c) and (d) on a straight line basis.

 

Share based payment charge attributable to directors in the year was £428,587 (2016: £267,301).

 

During the year, the committee received independent advice on executive remuneration matters from FIT Remuneration Consultants LLP. FIT received £7,099 in fees for these services.

 

 

 

 

Mike Inglis

Chairman of the Remuneration Committee

 

 

Statement of Directors' responsibilities in respect of the Annual Report and the Financial Statements

 

The Directors are responsible for preparing the annual report and the financial statements in accordance with applicable law and regulations.

 

Company law requires the Directors to prepare financial statements for each financial year. Under that law the Directors have elected to prepare the Group and Company financial statements in accordance with International Financial Reporting Standards ('IFRSs') as adopted by the European Union. Under company law the Directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Group and Company and of the profit or loss of the Group and Company for that period. The Directors are also required to prepare financial statements in accordance with the rules of the London Stock Exchange for companies trading securities on the Alternative Investment Market ('AIM').

 

In preparing these financial statements, the Directors are required to:

 

• select suitable accounting policies and then apply them consistently;

• make judgements and accounting estimates that are reasonable and prudent;

• state whether they have been prepared in accordance with IFRSs as adopted by the European Union, subject to any material departures disclosed and explained in the financial statements; and

• prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

 

The Directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and enable them to ensure that the financial statements comply with the requirements of the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

 

Website publication

The directors are responsible for ensuring the annual report and the financial statements are made available on a website. Financial statements are published on the Group's website in accordance with legislation in the United Kingdom governing the preparation and dissemination of financial statements, which may vary from legislation in other jurisdictions. The maintenance and integrity of the Group's website is the responsibility of the Directors. The Directors' responsibility also extends to the ongoing integrity of the financial statements contained therein.

 

Going concern

The directors have prepared and reviewed financial forecasts. After due consideration of these forecasts and current cash resources, the directors consider that the Company and the Group have adequate financial resources to continue in operational existence for the foreseeable future (being a period of at least twelve months from the date of this report), and for this reason the financial statements have been prepared on a going concern basis.

 

 

 

By order of the Board

 

 

 

 

Graeme Purdy

Chief Executive

11th July 2017

 

 

CORPORATE GOVERNANCE STATEMENT

Board of directors

The Board of directors (the 'Board') consists of a Non-Executive Chairman, three Executive Directors and three Non-Executive Directors.

 

The responsibilities of the Non-Executive Chairman and the Chief Executive Officer are clearly divided. The Chairman is responsible for overseeing the formulation of the overall strategy of the company, the running of the board, ensuring that no individual or group dominates the Board's decision making and ensuring that the non-executive directors are properly briefed on matters. Prior to each Board meeting, directors are sent an agenda and Board papers for each agenda item to be discussed. Additional information is provided when requested by the Board or individual directors.

The Chief Executive Officer has the responsibility for implementing the strategy of the Board and managing the day to day business activities of the Group through his chairmanship of the executive committee.

The Non-Executive Directors bring relevant experience from different backgrounds and receive a fixed fee for their services and reimbursement of reasonable expenses incurred in attending meetings.

The Board retains full and effective control of the Group. This includes responsibility for determining the Group's strategy and for approving budgets and business plans to fulfil this strategy. The full Board ordinarily meets bi-monthly.

The Company Secretary is responsible to the Board for ensuring that Board procedures are followed and that the applicable rules and regulations are complied with. All directors have access to the advice and services of the Company Secretary, and independent professional advice, if required, at the Company's expense. Removal of the Company Secretary would be a matter for the Board.

Performance evaluation

The Board has a process for evaluation of its own performance which is carried out annually.

 

Board Committees

As appropriate, the Board has delegated certain responsibilities to Board Committees as follows:

 

i) Audit Committee

 

The Audit Committee currently comprises Clare Spottiswoode CBE (Chairman), Professor Sir William Wakeham (Senior Independent Director), Professor Keith Jackson and Mike Inglis.

 

The Committee monitors the integrity of the Group's financial statements and the effectiveness of the audit process. The Committee reviews accounting policies and material accounting judgements. The Committee also reviews, and reports on, reports from the Group's auditors relating to the Group's accounting controls. It makes recommendations to the Board on the appointment of auditors and the audit fee. It has unrestricted access to the Group's auditors. The Committee keeps under review the nature and extent of non-audit services provided by the external auditors in order to ensure that objectivity and independence are maintained.

ii) Remuneration Committee

The Remuneration Committee comprised Mike Inglis (Chairman), Clare Spottiswoode CBE Professor Keith Jackson and Professor Sir William Wakeham (Senior Independent Director).

 

The committee is responsible for making recommendations to the Board on remuneration policy for Executive Directors and the terms of their service contracts, with the aim of ensuring that their remuneration, including any share options and other awards, is based on their own performance and that of the Group generally.

iii) Nomination Committee

 

The Nomination Committee comprised Mike Inglis (Chairman), Professor Sir William Wakeham (Senior Independent Director), Professor Keith Jackson and Clare Spottiswoode CBE.

 

It is responsible for providing a formal, rigorous and transparent procedure for the appointment of new directors to the board and reviewing the performance of the board each year.

 

Attendance at Board meetings and committees

 

The Directors attended the following Board and committees meetings during the year:

 

Attendance

Board*

Audit

Nomination

Remuneration

 

 

 

 

 

Mr S. Boydell

8/8

-

-

-

Prof. B. E. Hayden

7/8

-

-

-

Mr M Inglis

6/8

2/2

1/1

2/2

Mr G. Purdy

8/8

-

-

-

Ms. C Spottiswoode

7/8

2/2

1/1

2/2

Prof. Sir W Wakeham

7/8

2/2

1/1

2/2

Prof K Jackson

7/8

2/2

1/1

2/2

 

*One meeting in the year was to formally approve the allotment of the Placing and required only Mr G Purdy and Mr S Boydell to attend.

 

Risk management and internal control

 

The Board is responsible for the systems of internal control and for reviewing their effectiveness. The internal controls are designed to manage rather than eliminate risk and provide reasonable but not absolute assurance against material misstatement or loss. The Audit Committee reviews the effectiveness of these systems primarily by discussion with the external auditor and by considering the risks potentially affecting the Group.

 

The Group does not consider it necessary to have an internal audit function due to the small size of the administration function. Instead there is a detailed Director review and authorisation of transactions. The annual audit by the Group auditor, which tests a sample of transactions, did not highlight any significant system improvements in order to reduce risk.

 

The Group maintains appropriate insurance cover in respect of actions taken against the Executive Directors because of their roles, as well as against material loss or claims of the Group. The insured values and type of cover are comprehensively reviewed on a periodic basis.

 

By order of the Board

 

 

 

 

Mike Inglis

Chairman

11th July 2017

 

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF ILIKA PLC

 

We have audited the financial statements of Ilika plc for the year ended 30th April 2017 which comprise the Consolidated statement of comprehensive income, the Consolidated balance sheet, the Consolidated cash flow statement, the Consolidated statement of changes in equity, the Company balance sheet, the Company cash flow statement, the Company statement of changes in equity and the related notes. The financial reporting framework that has been applied in their preparation is applicable law and International Financial Reporting Standards (IFRSs) as adopted by the European Union and, as regards the parent company financial statements, as applied in accordance with the provisions of the Companies Act 2006.

 

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

 

Respective responsibilities of directors and auditors

 

As explained more fully in the statement of directors' responsibilities, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view. Our responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Financial Reporting Council's (FRC's) Ethical Standards for Auditors.

 

Scope of the audit of the financial statements

A description of the scope of an audit of financial statements is provided on the FRC's website at www.frc.org.uk/auditscopeukprivate.

 

 

Opinion on financial statements

In our opinion:

 

· the financial statements give a true and fair view of the state of the group's and the parent company's affairs as at 30th April 2017 and of the group's loss for the year then ended;

 

· the group financial statements have been properly prepared in accordance with IFRSs as adopted by the European Union;

 

· the parent company financial statements have been properly prepared in accordance with IFRSs as adopted by the European Union and as applied in accordance with the provisions of the Companies Act 2006; and

 

· the financial statements have been prepared in accordance with the requirements of the Companies Act 2006.

 

 

 

Opinion on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

 

· the information given in the Strategic report and Directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and

 

· the Strategic report and Directors' report have been prepared in accordance with applicable legal requirements.

 

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the group and the parent company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic report or the directors' report.

 

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

 

· adequate accounting records have not been kept by the parent company, or returns adequate for our audit have not been received from branches not visited by us; or

 

· the parent company financial statements are not in agreement with the accounting records and returns; or

 

· certain disclosures of directors' remuneration specified by law are not made; or

 

· we have not received all the information and explanations we require for our audit.

 

 

 

 

Malcolm Thixton (senior statutory auditor)

For and on behalf of BDO LLP, statutory auditor

Southampton

United Kingdom

 

 

 

BDO LLP is a limited liability partnership registered in England and Wales (with registered number OC305127). 

 

 

Consolidated statement of comprehensive income

 

 

 

 

Year ended 30th April

 

Notes

2017

2016

 

 

 

£

£

 

 

 

 

Turnover

2

1,050,667

605,924 

 

 

 

 

Revenue

 

311,946

150,931

UK grants

 

738,721

454,993

 

 

 

 

Cost of sales

 

(574,272)

(336,281)

 

 

-------

-------

Gross profit

 

476,395

269,643 

 

 

 

 

Administrative expenses

 

 

 

Administrative expenses

 

(3,863,411)

(3,776,950)

Share based payment charge

 

(547,347)

(352,291)

 

 

4,410,758

4,129,241 

 

 

-------

-------

Operating loss

3

(3,934,363)

(3,859,598)

 

 

 

 

Income from short term deposits

 

23,844

30,734 

 

 

-------

-------

Loss before tax

 

(3,910,519)

(3,828,864)

Taxation

5

370,274

357,896 

 

 

-------

-------

Loss for period / total comprehensive income attributable to owners of parent

 

(3,540,245)

(3,470,968)

 

 

-------

-------

Loss per share from continuing operations

6

 

 

Basic

 

(4.84)p

(5.23)p

Diluted

 

(4.84)p

(5.23)p

 

 

 

 

 

Consolidated balance sheet

Company number 7187804

 

 

 

As at 30th April

 

Notes

2017

2016

 

 

£

£

ASSETS

 

 

 

Non-current assets

 

 

 

Intangible assets

7

2,581 

15,595 

Property, plant and equipment

8

451,560 

399,324 

 

 

-------

-------

Total non-current assets

 

454,141 

414,919 

 

 

-------

-------

Current assets

 

 

 

Trade and other receivables

9

1,116,367 

517,695 

Current tax receivable

5

330,000 

375,000 

Other financial assets - bank deposits

 

2,900,000 

Cash and cash equivalents

10

2,510,884 

2,997,412 

 

 

-------

-------

Total current assets

 

6,857,251 

3,890,107 

 

 

-------

-------

Total assets

 

7,311,392 

4,305,026 

 

 

-------

-------

 

 

 

 

Issued capital and reserves attributable to owners of parent

 

 

 

Issued share capital

14

789,911 

663,911 

Share premium

 

23,179,756 

17,470,417 

Capital restructuring reserve

 

6,486,077 

6,486,077 

Retained earnings

 

(24,206,405)

(21,213,507)

 

 

-------

-------

Total equity

 

6,249,339 

3,406,898 

 

 

-------

-------

 

 

 

 

LIABILITIES

 

 

 

Current liabilities

 

 

 

Trade and other payables

11

912,053 

748,128 

Provisions

12

150,000 

150,000 

 

 

-------

-------

Total liabilities

 

1,062,053 

898,128 

 

 

-------

-------

Total equity and liabilities

 

7,311,392 

4,305,026 

 

 

-------

-------

 

The notes form part of these financial statements

 

These financial statements were approved and authorised for issue by the Board of Directors on 11th July 2017.

 

 

 

Mr. M Inglis

Chairman

 

Consolidated cash flow statement

 

Year ended 30th April

 

 

2017

2016

 

 

£

£

Cash flows from operating activities

 

 

 

Loss before taxation continuing operations

 

(3,910,519)

(3,828,864)

Adjustments for:

 

 

 

Amortisation

 

13,014

14,524 

Depreciation

 

192,331

257,274 

Equity settled share-based payments

 

547,347

352,291 

(Profit)/ loss on disposal of plant, property and equipment

 

(30,783)

1,049 

Financial income

 

(23,844)

(30,734)

 

 

-------

-------

Operating cash flow before changes in working capital, interest and taxes

 

(3,212,454)

(3,234,460)

Increase in trade and other receivables

(598,672)

(26,432) 

Increase in trade and other payables

163,925

19,257

 

 

-------

-------

Cash utilised by operations

 

(3,647,201)

(3,241,635)

 

 

 

 

Tax received

 

415,274

287,018 

 

 

-------

-------

Net cash flow used in operating activities

 

(3,231,927)

(2,954,617)

 

 

 

 

Cash flows from investing activities

 

 

 

Interest received

 

23,844

36,456 

Sale of property plant and equipment

40,129

-

Purchase of property, plant and equipment

(253,913)

(96,949)

(Increase)/ decrease in other financial assets

 

(2,900,000)

528,349 

 

 

-------

-------

Net cash (used in)/from investing activities

 

(3,089,940)

467,856 

 

 

 

 

Cash flows from financing activities

 

 

 

Proceeds from issuance of ordinary share capital

 

6,300,000 

5,138 

Cost of share issue

 

(464,661)

 

 

-------

-------

Net cash from financing activities

 

5,835,339 

5,138 

 

 

-------

-------

Net decrease in cash and cash equivalents

 

(486,528) 

(2,481,623)

Cash and cash equivalents at the start of the period

 

2,997,412 

5,479,035 

 

 

-------

-------

Cash and cash equivalents at the end of the period

 

2,510,884 

2,997,412 

 

 

-------

-------

     

 

 

Consolidated statement of changes in equity

 

 

Share

capital

Share

premium

account

Capital

restructuring reserve

Retained earnings

Total

attributable to equity holders of parent

 

£

£

£

£

£

 

 

 

 

 

 

As at 30th April 2015

663,748

17,465,442 

6,486,077 

(18,094,830)

6,520,437 

Share-based payment

-

-

352,291

352,291 

Issue of shares

163

4,975 

-

-

5,138 

Loss and total comprehensive income

-

-

(3,470,968)

(3,470,968)

 

------

-------

--------

--------

--------

As at 30th April 2016

663,911

17,470,417 

6,486,077 

(21,213,507)

3,406,898 

Share-based payment

-

-

-

547,347 

547,347 

Issue of shares

126,000

6,174,000

-

-

6,300,000 

Cost of share issue

-

(464,661)

-

-

(464,661)

Loss and total comprehensive income

-

-

-

(3,540,245)

(3,540,245)

 

------

-------

--------

--------

--------

As at 30th April 2017

789,911

23,179,756

6,486,077 

(24,206,405)

6,249,339

 

------

-------

--------

--------

--------

 

Share capital

The share capital represents the nominal value of the equity shares in issue.

 

Share premium account

When shares are issued, any premium paid above the nominal value is credited to the share premium reserve.

 

Capital restructuring reserve

The capital restructuring reserve arises on the accounting for the share for share exchange. It represents the difference between the value of the issued equity instruments of Ilika Technologies Limited immediately before the share for share exchange and the equity instruments of Ilika plc along with the shares issued to effect the share for share exchange.

 

Retained earnings

The retained earnings reserve records the accumulated profits and losses of the Group since inception of the business.

 

 

Notes to the consolidated financial statements

 

1. Accounting policies

Basis of preparation

These financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRSs") adopted by the European Union. The principal accounting policies adopted in the preparation of the consolidated financial statements are set out below. The policies have been consistently applied to all of the years presented.

 

 

Basis of consolidation

The consolidated financial statements incorporate the financial statements of the Company and entities controlled by the Company made up to the reporting date. The Company controls an investee if all three of the following elements are present: power over the investee, exposure to variable returns over the investee, and the ability of the investee to use its power to affect the variable returns. Control is reassessed whenever facts and circumstances indicate that there may be a change in any of these elements of control. All intra-group transactions, balances, income and expenses are eliminated on consolidation.

 

Going concern

The financial statements have been prepared on a going concern basis which assumes that the Company will have sufficient funds available to enable it to continue to trade for the foreseeable future. In making their assessment that this assumption is correct the Directors have undertaken an in depth review of the business, its current prospects, and cash resources as set out below.

 

The directors have prepared and reviewed financial forecasts. The Group meets its day to day working capital requirements through existing cash resources which, at 30th April 2017, amounted to £5,410,884. After due consideration of these forecasts and current cash resources, the directors consider that the Company and the Group have adequate financial resources to continue in operational existence for the foreseeable future (being a period of at least twelve months from the date of this report), and for this reason the financial statements have been prepared on a going concern basis.

 

The Directors have also considered the likely sales, contracts and announcements that the Company anticipate being able to make over the coming months, the current share price, levels of trading in the Company's shares and past history of raising funds with the Company's Brokers.

 

After taking account of all the above factors the Directors believe that as the market becomes more aware of the Company' prospects and the scale of the opportunities that the Company's technologies create the Company will continue to be able to raise any funds required to enable it to continue to trade and grow towards self-sufficiency.

 

Changes in accounting policies

 

(a) New standards, amendments to standards or interpretations adopted early

 

During the period ended 30th April 2017, there were no new or revised standards, amendments to standards or interpretations that have been adopted and affected the amounts reported in the financial statements.

(b) New standards, amendments to standards or interpretations not yet applied

 

The following standards, interpretations and amendments, which have not been applied in these financial statements and have an effective date commencing after 1st May 2017, will or may have an effect on the Group's future financial statements:

 

 

International Accounting Standards (IAS/IFRS)

 

Effective date for

periods commencing

IFRS 15

Revenue from Contracts with Customers

1 January 2018

   

 

The directors will assess the impact of IFRS 15, with particular focus on the recognition of revenue over the life of contracts and projects.

 

No other new standards or amendments are expected to have an effect on the Group.

 

Revenue

 

Revenue comprises the fair value for the sale of services, net of value added tax and is recognised as follows:

 

Sales of services

Sales of research and development services are recognised in the accounting period in which the services are rendered, by reference to completion of the specific transaction assessed on the basis of the actual service provided as a proportion of the total services to be provided.

 

Government grants

Grants that compensate the Group for expenses incurred are recognised in the income statement on a systematic basis in the same periods in which the expenses are recognised.

 

 

Financial income

 

Financial income is recognised in the income statement as it accrues, using the effective interest method.

 

Pension and other post retirement benefits

 

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

 

Share-based payment transactions

The Group issues equity-settled share options to all employees. Equity-settled share options are measured at fair value at the date of grant. The fair value determined at the grant date of the equity-settled share options is expensed on a straight-line basis over the vesting period, based on the Group's estimate of shares that will eventually vest and adjusted for the effect of non-market based vesting conditions.

 

The fair value of non market-based options granted by the Group is measured by use of the Black-Scholes pricing model taking into account the following inputs: the exercise price of the option; the life of the option; the market price on the date of grant of the option; the expected volatility of the share price; the dividends expected on the shares; and the risk free interest rate for the life of the option. The expected life used in the model has been adjusted, based on management's best estimate, for the effects of non-transferability, exercise restrictions, and behavioural considerations.

 

Research and development expenditure

Research expenditure is recognised as an expense when it is incurred.

 

Development expenditure is recognised as an expense except that costs incurred on development projects are capitalised as intangible assets to the extent that such expenditure is expected to generate future economic benefits. Development expenditure is capitalised if, and only if, an entity within the Group can demonstrate all of the following:

i. Its ability to measure reliably the expenditure attributable to the asset under development;

ii. The product or process is technically and commercially feasible;

iii. Its future economic benefits are probable;

iv. Its ability to use or sell the developed asset;

v. The availability of adequate technical, financial and other resources to complete the asset under development; and

vi. Its intention is to use or sell the developed asset.

Prior to and during the year ended 30th April 2017, no development expenditure satisfied all of these conditions.

 

Taxation

Companies within the group may be entitled to claim special tax allowances in relation to qualifying research and development expenditure (eg R&D tax credits). The group accounts for such allowances as tax credits, which means that they are recognised when it is probable that the benefit will flow to the group and that benefit can be reliably measured. R&D tax credits reduce current tax expense and, to the extent the amounts due in respect of them are not settled by the balance sheet date, reduce current tax payable. A deferred tax asset is recognised for unclaimed tax credits that are carried forward as deferred tax assets.

 

Deferred tax is provided on temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The amount of deferred tax provided is based on the expected manner of realisation or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantively enacted at the reporting date.

 

A deferred tax asset is recognised only to the extent that it is probable that future taxable profits will be available against which the asset can be utilised.

 

Foreign currency

Transactions in foreign currencies are translated at the foreign exchange rate ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the balance sheet date are translated at the foreign exchange rate ruling at that date. Foreign exchange differences arising on translation are recognised in profit or loss.

Property, plant and equipment

Property, plant and equipment are stated at cost less accumulated depreciation and impairment losses.

 

Where parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items of property, plant and equipment.

 

Depreciation is charged to the statement of comprehensive income on a straight-line basis over the estimated useful lives of each part of an item of property, plant and equipment less their estimated residual value. The estimated useful lives are as follows:

 

Leasehold improvements lease term

Plant, machinery and equipment 3 - 5 years

Fixtures & fittings 3 - 5 years

 

Impairment

The carrying amounts of the Group's assets are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, the asset's recoverable amount is estimated at the present value of the future expected cashflows associated with the impaired asset.

 

An impairment loss is recognised whenever the carrying amount of an asset exceeds its recoverable amount. Impairment losses are recognised in the profit and loss account.

 

Intangible assets

Computer software

Acquired computer software licenses are capitalised on the basis of the costs incurred to acquire and bring to use the specific software. These costs are amortised to administrative expenses using the straight line method over their estimated useful lives (1-3 years).

 

 

Intellectual property

Acquired intellectual property is included at cost and is amortised to administrative expenses on a straight-line basis over its useful economic life of 15 years.

Financial instruments

Financial assets and financial liabilities are recognised on the Group's balance sheet when the Group becomes a party to the contractual provisions of the instrument. The Group's financial assets are all classified as loans and receivables and carried at amortised cost. The Group's financial liabilities are all classified as 'other' liabilities which are carried at amortised cost. Cash and cash equivalents comprise cash balances and call deposits. Deposits of over 3 months' maturity, judged at inception, are classified as Other Financial Assets.

 

Key sources of estimation and uncertainty

The preparation of the Group's financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses at the date of the Group's financial statements. The Group's estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

 

The directors do not believe there to be any estimates or judgements that have a significant impact on the Group's Financial statements.

 

2. Segment reporting

The Group operates in one area of activity, namely the production, design and development of high throughput methods of material synthesis, characterisation and screening. The Group has materials development programmes addressing a wide range of applications including the solid-state battery, aerospace alloys and electronic materials.

 

For management purposes, the Group is analysed by the geographical location of its customer base and business development directors have been appointed to cover the group's three territories of focus, Asia, North America and Europe.

 

 

Year ended 30th April

Revenue

2017

2016

 

£

£

Analysis by geographical market:

 

By destination

 

 

Asia

21,280

74,162 

Europe

-

23,355 

North America

197,818

7,702 

UK

831,569

500,705 

 

------ 

-------

 

1,050,667

605,924 

 

-------

-------

 

 

 

 

A number of customers individually account for more than 10% of the total turnover of the Group. The revenues from these companies are indicated below:

 

 

 

 

Year ended 30th April

Revenue

2017

2016

 

£

£

 

 

 

UK Grants

738,721

454,993 

Customer 2

197,819

74,150 

Customers less than 10%

114,127

76,781 

 

-------

-------

 

1,050,667

605,924 

 

-------

-------

 

3. Operating loss

 

Year ended 30th April

 

2017

2016

This is arrived at after charging:

£

£

 

 

 

Research and development expenditure in the year

2,110,843

2,057,966 

Depreciation

192,331

257,274 

Amortisation of intangible assets

13,014

14,524 

Auditors remuneration:

Fees payable to the Group's auditor for the audit of the Group's accounts

 

20,700 

 

19,700 

Fees payable to the Group's auditor for other services:

- The Audit of the Group's subsidiaries

- All other services

 

6,800 

 

6,800 

21,518 

Operating lease rentals

207,511 

204,578 

Share-based payment

547,347 

352,291 

 

-------

-------

 

4. Employees

 

The average number of employees during the year, including executive directors, was:

 

 

Year ended 30th April

 

2017

2016

 

Number

Number

Administration

6

8

Materials synthesis

32

27

 

------

------

 

38

35

 

------

------

Staff costs for all employees, including executive directors, consist of:

 

Year ended 30th April

 

2017

2016

 

£

£

 

 

 

Wages and salaries

1,954,655

1,813,889

Social security costs

215,648

183,594

Share-based payment expense

532,347

337,291

Pension costs

139,286

119,664

 

-------

-------

 

2,841,936

2,454,438

 

--------

--------

The total remuneration of the Directors of the Group was as follows:

 

 

Year ended 30th April

 

2017

2016

 

£

£

 

 

 

Wages and salaries

624,726

607,703

Pension costs

47,534

47,181

 

-------

-------

Directors' emoluments

672,260

654,884

 

 

 

Social security costs

80,177

77,420

Share-based payment expense

428,587

267,301

 

-------

-------

Key management personnel

1,181,024

999,605

 

--------

--------

The Directors represent key management personnel and further details are given in the Directors' Remuneration Report.

 

5. Taxation

(a) Tax on loss from ordinary activities

 

There is no taxation charge due to the losses incurred by the Group during the year. The taxation credit represents R&D tax credit claims as follows:

 

Year ended 30th April

 

2017

2016

 

£

£

 

 

 

Current tax on loss for the year

330,000

329,473

Adjustments to prior period

40,274

28,423

 

------

------

 

370,274

357,896

 

------

------

 

(b) Factors affecting current tax charge

 

The tax assessed on the loss on ordinary activities for the period is different to the standard rate of corporation tax in the UK of 20% (2016: 20%). The differences are reconciled below:

 

 

2017

2016

 

£

£

 

 

 

Loss on ordinary activities before tax

(3,910,519)

(3,828,864)

 

------

------

Loss on ordinary activities before tax multiplied by the standard rate of corporation tax in the UK of 20% (2016: 20%)

 

(778,975)

 

(765,773)

Effects of:

 

 

Expenses not deductible for corporation tax

109,098 

71,179 

R&D relief

(289,726)

(329,473)

Origination of unrecognised tax losses

629,603 

694,594 

Under provision in previous years

(40,274)

(28,423)

 

------

------

Total tax credit for the year

(370,274)

(357,896)

 

------

------

 

Unrecognised deferred taxation

 

There are tax losses available for carry forward against future trading profits of approximately £19,065,000 (2016: £17,009,000). A deferred tax asset in respect of these losses of approximately £3,240,000 (2016: £3,062,000) has not been recognised in the accounts, as the full utilisation of these losses in the foreseeable future is uncertain.

 

6. Loss per share

Earnings per ordinary share have been calculated using the weighted average number of shares in issue during the relevant financial periods. The weighted average number of equity shares in issue and the earnings, being loss after tax, are as follows:

 

Year ended 30th April

 

2017

2016

 

No.

No.

 

 

 

Weighted average number of equity shares

73,122,617 

66,378,114

 

--------

--------

 

 

 

 

£

£

Earnings, being loss after tax

(3,540,245)

(3,470,968)

 

--------

--------

 

 

 

 

Pence

Pence

Loss per share

(4.84)

(5.23)

 

------

------

The loss attributable to ordinary shareholders and weighted average number of ordinary shares for the purpose of calculating the diluted earnings per ordinary share are identical to those used for basic earnings per share. This is because the exercise of share options would have the effect of reducing the loss per ordinary share and is therefore not dilutive. At 30th April 2017, there were 7,741,892 options outstanding (2016: 6,988,112) as detailed in notes 14 and 18.

 

7. Intangible assets

 

 

Software

licences

Intellectual property

Total

 

 

£

£

£ 

Cost

 

 

 

 

As at 30th April 2015

54,365 

75,000 

129,365 

Disposals

 

(8,072)

-

(8,072)

 

 

------

------

------ 

As at 30th April 2016

 

46,293 

75,000 

121,293 

Disposals

 

(7,250)

 

(7,250)

 

 

------

------

------

As at 30th April 2017

 

39,043 

75,000 

121,293 

 

 

------

------

------

Amortisation

 

 

 

 

As at 30th April 2015

 

24,246 

75,000

99,246 

Provided for the year

 

14,524 

-

14,524 

Disposals

 

(8,072)

-

(8,072)

 

 

------

------

------

As at 30th April 2016

 

30,698 

75,000

105,698 

Provided for the year

 

13,014 

-

13,014 

Disposals

 

(7,250)

-

(7,250)

 

 

------

------

------

As at 30th April 2017

 

36,462 

75,000

111,462 

 

 

------

------

------

Net book value

 

 

 

 

As at 30th April 2015

 

30,119 

-

30,119 

 

 

------

------

------

As at 30th April 2016

 

15,595 

-

15,595 

 

 

------

------

------

As at 30th April 2017

 

2,581 

-

2,581 

 

 

------

------

------

 

The amortisation charge of £13,014 (2016: £14,524) is included within administrative expenses.

 

 

 

8. Property, plant and equipment

 

Leasehold

improvements

Plant,

machinery and equipment

Fixtures and fittings

Total

 

£

£

£ 

£

Cost

 

 

 

 

As at 30th April 2015

567,500

4,426,077 

171,790

5,165,367

Additions

-

96,949 

-

96,949

Disposals

-

(4,265)

(4,265)

 

------

-------

------

-------

As at 30th April 2016

567,500

4,523,026 

167,525

5,258,051

Additions

-

253,172 

741

253,913

Disposals

-

(234,408)

(546)

(234,954)

 

------

-------

------

-------

As at 30th April 2017

567,500

4,541,790 

167,720

5,277,010

 

------

-------

------

-------

Depreciation

 

 

 

 

As at 30th April 2015

567,500

3,881,155

156,014

4,604,669

Provided for the year

-

250,492

6,782

257,274

Disposals

-

-

(3,216)

(3,216)

 

------

-------

------

-------

As at 30th April 2016

567,500

4,131,647 

159,580

4,858,727

Provided for the year

-

187,591 

4,740

192,331

Disposals

-

(225,062)

(546)

(225,608)

 

------

-------

------

-------

As at 30th April 2017

567,500

4,094,176 

163,774

4,825,450

 

------

-------

------

-------

 

 

 

 

 

Net book value

 

 

 

 

As at 30th April 2015

544,922 

15,776

560,698

 

------

-------

------

-------

As at 30th April 2016

391,379 

7,945

399,324

 

------

-------

------

-------

As at 30th April 2017

447,614 

3,946

451,560

 

------

-------

------

-------

 

 

 

 

 

 

There are no commitments for capital expenditure contracted but not provided for (2016 - £nil)

 

 

9. Trade and other receivables

 

As at 30th April

 

2017

2016

 

£

£

 

 

 

Trade receivables

133,655

27,976

Prepayments

299,032

215,933

Other receivables

312,769

156,863

Accrued income

370,911

116,923

 

------

------

 

1,116,367

517,695

 

------

------

 

 

The ageing of trade receivables is as follows:

 

As at 30th April

 

2017

2016

 

£

£

 

 

 

0-29 days

67,181 

4,621

30-59 days

66,474 

23,355

 

------

------

 

133,655 

27,976

 

------

------

 

Included in other receivables is an amount of £150,000 (2016: £75,000) which represents cash held in a separate bank account used as security against a bond provided by the Company's bankers (refer note 12). The bond relates to the potential dilapidations costs due at the end of the Company's property lease

 

10. Cash and cash equivalents

 

As at 30th April

 

2017

2016

 

£

£

 

 

 

Current bank accounts

238,371 

125,018

Short term deposits with less than three months' maturity

2,272,513 

2,872,394

 

--------

--------

 

2,510,884 

2,997,412

 

--------

--------

 

 

 

 

11. Trade and other payables

 

As at 30th April

 

2017

2016

 

£

£

 

 

 

Trade payables

308,635

197,117 

Other payables

28,454

14,654 

Other taxes and social security costs

57,768

44,976 

Accruals

517,196

491,381 

 

--------

--------

 

912,053

748,128 

 

--------

--------

 

The ageing of financial liabilities is as follows:

 

As at 30th April

 

2017

2016

 

£

£

 

 

 

0-29 days

562,725

390,618

30-59 days

163,854

61,039

60-89 days

3,010

21,495

90+ days

124,696

230,000

 

--------

--------

 

854,285

703,152

 

--------

--------

 

 

12. Provisions

 

 

Leasehold

 Dilapidations

 

 

£

 

 

 

As at 1st May 2016 and at 30th April 2017

 

150,000

 

 

------

 

All provisions are due within one year.

 

Leasehold dilapidations relate to the estimated cost of returning a leasehold property to its original state at the end of the lease in accordance with the lease terms.

 

13. Financial instruments

The risks associated with financial instruments are set out below.

 

Foreign currency risk

The Group buys goods and services in currencies other than sterling. The Group's non sterling liabilities and cash flows can be affected by movements in exchange rates. The Group has denominated some of it sales transactions in non sterling currencies and has entered into a forward exchange contract to mitigate this risk.

 

Credit risk

The Group's credit risk is attributable to its trade receivables and banking deposits. The Group places its deposits with reputable financial institutions to minimise credit risk. The maximum exposure to credit risk for each period is the amount disclosed above as total loans and receivables. For the periods above there were no trade receivables which were past due or impaired. Risk is further mitigated through the use of credit limits, but also through the nature of the customers, who, for the most part, are large multinationals.

 

Liquidity risk

The Group's policy is to maintain adequate cash resources to meet liabilities as they fall due. All Group payable balances fall due for payment within one year. Cash balances are placed on deposit for varying periods with reputable banking institutions to ensure there is limited risk of capital loss. The Group does not maintain an overdraft facility.

 

Interest rate risk

The main risk arising from the Group's financial instruments is interest rate risk. The Group placed deposits surplus to short-term working capital requirements with a variety of reputable UK-based banks. These balances are placed at floating rates of interest and deposits have maturities of one to twelve months. The Group's cash and short-term deposits are set out in note 11. Floating-rate financial assets comprise cash on deposit and cash at bank. Short-term deposits are placed with banks for periods of up to 12 months and are categorised as floating-rate financial assets. Contracts in place at 30th April 2017 had a weighted average period to maturity of 26 days (2016: 30 days) and a weighted average annualised rate of interest of 0.6%. (2016: 0.7%)

 

Interest rate risk sensitivity analysis

It is estimated that a change in base rate to zero would have increased the Group's loss before taxation for the year to 30th April 2017 by approximately £24,000 (2016: £31,000).

 

It is estimated that an increase in base rate by 1 percent would decrease the Group's loss before taxation for the year to 30th April 2017 by approximately £45,000 (2016: £42,000)

 

There is no difference between the book and fair value of financial assets and liabilities.

 

Capital management

The primary aim of the Group's capital management is to safeguard the Group's ability to continue as a going concern, to support its businesses and maximise shareholder value. The Group monitors its capital structure and makes adjustments as and when it is deemed necessary and appropriate to do so using such methods as the issuing of new shares. At present all funding is raised by equity.

 

 

 

 

14. Share capital

 

As at 30th April

 

2017

2016

 

£

£

Authorised

 

 

78,402,710 Ordinary Shares of £0.01 each (2016: 65,802,710)

784,027

658,027

1,781,400 Convertible Preference Shares of £0.01 each

17,814

17,814

 

------

------

Allotted, called up and fully paid

 

 

78,402,710 Ordinary Shares of £0.01 each (2016: 65,802,710)

784,027

658,027

588,400 Convertible Preference Shares of £0.01 each (2016: 588,400)

5,884

5,884

 

------

------

 

789,911

663,911

 

------

------

 

Share Rights

 

The ordinary share and preference shares rank pari passu in all respects other than:

 

· The profits which the Group may determine to distribute in respect of any financial period shall be distributed only among the holders of the Ordinary Shares. The Preference Shares shall not entitle the holders of them to any share in such distributions

· On a return of capital or assets on a liquidation, reduction of capital or otherwise the surplus assets of the Group remaining after payment of its obligations shall be applied:

o First, in paying to the holders of the Preference Shares the amount paid thereon, being the amount equal to the par value of the preference shares excluding any premium; and

o Secondly, the balance of such surplus assets shall belong to and be distributed amongst the holders of the Ordinary Shares.

 

The Preference Share holders have the right, at any time, to convert the preference shares held to the same number of Ordinary Shares.

 

On 18th October 2016, 12,600,000 Ordinary Shares of £0.01 each were issued for a total consideration of £6,300,000 and total costs incurred were £464,661.

 

Share options and warrants

 

Employee related share options are disclosed in note 18. In addition to these, there were 107,300 non employee share options over ordinary shares of £0.01 at the year end.

 

 

 

15. Operating leases

 

The total future minimum rent payable under non-cancellable operating leases is as follows:

 

 

2017

2016

 

£

£

Property leases which expire:

 

 

Within one year

97,143

 

------

------

 

16. Pensions

 

The Group operates a defined contribution group personal pension scheme. The pension cost charge for the period represents contributions payable by the Group to the scheme and amounted to £139,286 (2016: £119,664).

 

17. Related party transactions

 

The directors consider that no one party controls the Group.

 

Details of key management personnel and their compensation are given in note 4 and in the Directors' Remuneration Report.

 

18. Share-based payments expense and share options

 

Share-based payment expense

 

The Group has incentivised and motivated staff through the grant of share options under the Enterprise Management Incentive (EMI) scheme and through unapproved share options.

 

At 30th April 2017, the following options, whose fair values have been fully charged to the consolidated statement of total comprehensive income, were outstanding:

 

Approved share options:

Date of grant

Number of shares

Period of

 option

Exercise

Price per share

14/05/07

156,100

10 years

£0.80

15/01/08

22,400

10 years

£1.00

02/02/09

58,000

10 years

£0.80

01/12/09

90,000

10 years

£0.80

14/05/10

26,100

10 years

£0.51

01/02/12

39,634

10 years

£0.53

 

 

 

 

 

 

 

Unapproved share options:

Date of grant

Number of shares

Period of

 option

Exercise

Price per share

11/07/07

195,500

10 years

£0.80

11/11/08

40,000

10 years

£2.4283

14/05/10

1,897,800

10 years

£0.51

 

 

Black Scholes valuation

 

Weighted Average Exercise Price

Number

 

2017

2016

2017

2016

Outstanding:

£

£

 

 

At start of the period

0.5021

0.8341

4,956,912 

2,188,148 

Granted in the period

0.4850

0.2567

906,500 

2,867,908 

Exercised in the period

-

0.2732

(13,394)

Lapsed in the period

0.7384

0.8032

(152,720)

(85,750)

 

-----

-----

--------

--------

At the end of the period

0.4930

0.5021

5,710,692 

4,956,912 

 

-----

-----

--------

--------

 

The exercise price of options outstanding at the end of the period ranged between £0.01 and £2.4283 and their weighted average contractual life was 8.1 years (2016: 8.8 years). These share options are exercisable and must be exercised within 10 years from the date of grant.

 

Stochastic valuation

 

Weighted Average Exercise Price

Number

 

2017

2016

2017

2016

Outstanding:

£

£

 

 

At start of the period

0.51

0.51

1,923,900

2,989,300 

Exercised in the period

-

0.51

-

(2,900)

Lapsed during the period

-

0.51

-

(1,062,500)

 

----

----

---------

---------

At the end of the period

0.51

0.51

1,923,900

1,923,900 

 

----

----

---------

---------

 

The exercise price of options outstanding at the end of the period was £0.51 (2016: £0.51) and their weighted average contractual life was 4 years (2016: 5 years).

 

 

 

Ilika plc Executive Share Option Scheme 2010

 

At 30th April 2017 the following share options were outstanding in respect of the Ilika plc Executive Share Option Scheme 2010:

Date of grant

Number of shares

Period of option

Exercise

Price per share

14/05/10

26,100

10 years

£0.51

01/02/12

39,634

10 years

£0.53

26/02/15

1,208,750

10 years

£0.815

22/03/16

981,000

10 years

£0.59

16/03/17

906,500

10 years

£0.485

 

Members of staff in the Group have options in respect of ordinary shares in Ilika plc, which are conditional upon the achievement of a series of financial and commercial milestones.

 

152,720 options lapsed in the year.

 

Ilika plc unapproved share options

 

At 30th April 2017 the following share options were outstanding in respect of Ilika plc unapproved share options:

Date of grant

Number of shares

Period of option

Exercise

Price per share

 

 

 

 

11/07/07

195,500

10 years

£0.80

11/11/08

40,000

10 years

£2.4283

14/05/10

1,897,800

10 years

£0.51

26/02/15

177,900

10 years

£0.815

30/09/15

160,000

10 years

£0.688

30/09/15

1,674,908

10 years

£0.01

 

No options lapsed or were exercised in the year.

 

There are 2,525,534 options which were capable of being exercised as at 30th April 2017.

 

 

2017

2016

 

£

£

Share-based payment expense

 

 

Black Scholes calculation

547,347 

352,291

 

------

------

 

 

Company Balance sheet of Ilika plc

Company number 7187804

 

 

 

As at 30th April

 

 

Notes

2017

£

2016

£

ASSETS

 

 

 

Non current assets

 

 

 

Investments in subsidiary undertaking

21

121,339

121,339

Amount due from subsidiary undertaking

23

24,108,345

18,234,671

 

 

-------

-------

 

 

24,229,684

18,356,010

Current assets

 

 

 

Trade and other receivables

22

13,646

2,518

 

 

-------

-------

Total assets

 

24,243,330

18,358,528

 

 

-------

-------

Equity

 

 

 

Issued share capital

 

789,911

663,911

Share premium

 

23,158,967

17,449,628

Retained earnings

 

146,304 

108,683 

 

 

-------

-------

 

 

24,095,182

18,222,222

LIABILITIES

 

 

 

Current liabilities

 

 

 

Trade and other payables

24

148,148

136,306

 

 

-------

-------

Total liabilities

 

148,148

136,306

 

 

-------

-------

Total equity and liabilities

 

24,243,330

18,358,528

 

 

-------

-------

 

No profit and loss account is presented for the Company as permitted by Section 408 of the Companies Act 2006. The Company's loss for the year was £509,726 (2016: loss of £318,884).

 

The notes form part of these financial statements.

 

These financial statements were approved and authorised for issue by the Board of Directors on 11th July 2017.

 

 

 

 

 

Mr. M Inglis

Chairman

 

 

 

 

 

 

Year ended 30th April

 

 

2017

2016

 

 

£

£

Cash flows from operating activities

 

 

 

Loss before tax

 

(509,726)

(318,884)

Adjustments for:

 

 

 

Equity settled share-based payments

 

547,347 

352,291 

 

 

------

------

Operating cash flow before changes in working capital, interest and taxes

 

37,621 

33,407 

 

 

 

 

(Increase)/ decrease in trade and other receivables

(11,127)

3,699 

Increase in trade and other payables

11,842 

2,955 

Increase in amounts due from subsidiary undertaking

(5,873,675)

(45,199)

 

 

------

------

Cash utilised by operations

 

(5,835,339)

(5,138)

 

 

 

 

Cash flows from financing activities

 

 

 

Proceeds from issuance of ordinary share capital

 

6,300,000 

5,138 

Costs of share issue

 

(464,661)

 

 

------

------

Net cash from financing activities

 

5,835,339 

5,138 

 

 

------

------

Net increase in cash and cash equivalents

 

-

-

Cash and cash equivalents at the start of the period

 

-

-

 

 

------

------

Cash and cash equivalents at the end of the period

 

-

-

 

 

------

------

Company cashflow statement

 

 

Company statement of changes in equity

 

 

 

Share

capital

Share

premium

account

 

Retained

Earnings

Total

attributable to

equity holders

 

£

£

£

£

 

 

 

 

 

As at 30th April 2015

663,748

17,444,653

75,276

18,183,677

Issue of shares

163

4,975

-

5,138

Share-based payment

-

-

352,291

352,291

Profit and total comprehensive income

-

-

(318,884)

(318,884)

 

------

------

------

-------

As at 30th April 2016

663,911

17,449,628

108,683

18,222,222

 

 

 

 

 

Issue of shares

126,000

6,174,000

-

6,300,000

Costs of issue

-

(464,661)

-

(464,661)

Share-based payment

-

-

547,347

547,347

Profit and total comprehensive income

-

-

(509,726)

(509,726)

 

------

------

------

-------

As at 30th April 2017

789,911

23,158,967

146,304

24,095,182

 

------

------

------

------

 

Share capital

The share capital represents the nominal value of the equity shares in issue.

 

Share premium account

When shares are issued, any premium paid above the nominal value is credited to the share premium reserve.

 

Retained earnings

The retained earnings reserve records the accumulated profits and losses of the Company since inception of the business.

 

Notes to the financial information

 

19. Accounting polices

 

Basis of preparation

 

These financial statements have been prepared in accordance with International Financial Reporting Standards (''IFRSs'') adopted by the European Union.

 

Taxation, share based payments and financial instruments

 

For the relevant accounting policies please see note 1

 

Investments in subsidiary undertakings

 

Investments in subsidiary undertakings where the Company has control are stated at cost less any provision for impairment.

 

20. Directors' remuneration

 

The only employees of the Company are the directors. In respect of directors' remuneration, the disclosures required by Schedule 5 to the Large and Medium-sized Companies and Groups (Accounts and Reports) Regulations 2008 are included in the detailed disclosures in the audited section of the Directors' Remuneration Report, which are ascribed as forming part of these financial statements.

 

21. Investment in subsidiary undertaking

 

Investments in Group undertakings are stated at cost.

 

Ilika plc has a wholly owned subsidiary, Ilika Technologies Limited. Ilika Technologies Limited (Incorporated in the UK) made a loss for the year of £3,030,519 (2016: £3,152,084) and had net liabilities as at 30th April 2017 of £17,724,504 (2016: £14,693,985).

 

2017

2016

Shares in Group undertakings (at cost)

£

£

 

 

 

At 1st May 2016 and 30th April 2017

121,339

121,339

 

------

------

The registered address of Ilika Technologies Limited is Kenneth Dibben House, Enterprise Road, University of Southampton Science Park, Chilworth, Southampton, SO16 7NS.

 

22. Trade and other receivables

 

2017

2016

 

£

£

 

 

 

Prepayments

13,646 

2,518 

 

------

------

23. Amount due from subsidiary undertaking

 

2017

2016

 

£

£

 

 

 

Ilika Technologies Limited

24,108,345

18,234,670 

 

------

------

24. Trade and other payables

 

2017

2016

 

£

£

 

 

 

Trade payables

32,903

6,019

Accruals

115,245

130,287

 

------

------

 

148,148

136,306

 

25. Related party transactions

 

During the year the Company recharged costs totalling £163,744 (2016: £168,375) to its subsidiary, Ilika Technologies Limited. Amounts owed to Ilika Technologies Limited are disclosed in note 23.

 

Details of key management personnel and their compensation are given in the Directors' Remuneration Report.

 

The directors consider that no one party controls the Company.

 

26. Financial instruments

 

Credit risk

The Company's credit risk is attributable to its receivable of £24,108,345 from its subsidiary undertaking, Ilika Technologies Limited. As at 30th April 2017, Ilika Technologies Limited had net liabilities of £17,724,504. The Company makes no allowance for impairment of this balance. Impairment is considered by management based on prior experience, current market and third party intelligence while considering the current economic environment.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FR OKKDDCBKDPOD
Date   Source Headline
27th Mar 20247:00 amRNSNotice of Capital Markets Day and Investor Q&A
23rd Jan 20247:00 amRNSHalf-year Report
15th Jan 20247:00 amRNS2024 Conference Schedule
14th Dec 20231:46 pmRNSAward of Share Options, Exercise of Options & TVR
13th Dec 20231:43 pmRNSHolding(s) in Company
6th Dec 20237:00 amRNSLithium-ion parity development milestone
24th Nov 20237:00 amRNSTrading Update, Notice of Results & Presentations
20th Nov 20237:00 amRNSKey Technology Development Milestone
9th Oct 20237:00 amRNSAward of Scale-up Grant Funding for Goliath
20th Sep 20233:20 pmRNSResult of AGM & Award of Executive Share Options
18th Aug 20237:00 amRNSPosting of Annual Report and Notice of AGM
4th Aug 20237:00 amRNSSigned agreement with Cirtec Medical
13th Jul 20237:00 amRNSFinal Results
16th Jun 20237:00 amRNSSenior appointment&conversion of preference shares
22nd May 20237:00 amRNSTrading Update & Notice of Results
11th May 20237:00 amRNSFirst Customer Shipments of Stereax M300 Batteries
26th Apr 20237:00 amRNSExercise of Options and Total Voting Rights
11th Apr 20237:00 amRNSFirst Customer Shipment of Stereax® Batteries
8th Mar 20234:35 pmRNSPrice Monitoring Extension
1st Mar 20237:00 amRNSAward of Share Options
31st Jan 202310:30 amRNSDirector/PDMR Shareholding
30th Jan 20232:05 pmRNSSecond Price Monitoring Extn
30th Jan 20232:00 pmRNSPrice Monitoring Extension
30th Jan 202311:05 amRNSSecond Price Monitoring Extn
30th Jan 202311:00 amRNSPrice Monitoring Extension
26th Jan 20232:05 pmRNSSecond Price Monitoring Extn
26th Jan 20232:00 pmRNSPrice Monitoring Extension
26th Jan 202311:05 amRNSSecond Price Monitoring Extn
26th Jan 202311:00 amRNSPrice Monitoring Extension
26th Jan 20239:05 amRNSSecond Price Monitoring Extn
26th Jan 20239:00 amRNSPrice Monitoring Extension
26th Jan 20237:00 amRNSAward of Grant Funding for Goliath
19th Jan 20237:00 amRNSHalf-year Report
16th Jan 20237:00 amRNSMOU signed with Cirtec Medical
9th Jan 20234:40 pmRNSSecond Price Monitoring Extn
9th Jan 20234:35 pmRNSPrice Monitoring Extension
28th Dec 20224:40 pmRNSSecond Price Monitoring Extn
28th Dec 20224:35 pmRNSPrice Monitoring Extension
28th Dec 20222:05 pmRNSSecond Price Monitoring Extn
28th Dec 20222:00 pmRNSPrice Monitoring Extension
19th Dec 20224:40 pmRNSSecond Price Monitoring Extn
19th Dec 20224:35 pmRNSPrice Monitoring Extension
16th Dec 20224:40 pmRNSSecond Price Monitoring Extn
16th Dec 20224:35 pmRNSPrice Monitoring Extension
21st Nov 20221:29 pmEQSIlika 'well positioned' to deliver battery product combination
17th Nov 20224:40 pmRNSSecond Price Monitoring Extn
17th Nov 20224:35 pmRNSPrice Monitoring Extension
17th Nov 20229:05 amRNSSecond Price Monitoring Extn
17th Nov 20229:00 amRNSPrice Monitoring Extension
17th Nov 20227:01 amRNSAppointment of Chief Financial Officer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.